Covid: Ema begins examination of Merck's drug

(ANSA) - BRUSSELS, OCTOBER 25 - The European Medicines Agency (Ema) has started the real-time review of data on the oral antiviral drug molnupiravir developed by Merck Sharp & Dohme, in collaboration with Ridgother Biotherapeutics for the treatment of Covid ‑ 19 in adults .

This was announced by the EMA.

   According to the first results of the trials, the drug can prevent hospitalization or death in patients.

(HANDLE).